Flexion Therapeutics Inc (FLXN) : Novo As scooped up 147,557 additional shares in Flexion Therapeutics Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Nov 14, 2016. The investment management firm now holds a total of 1,097,718 shares of Flexion Therapeutics Inc which is valued at $23,019,146.Flexion Therapeutics Inc makes up approximately 2.06% of Novo As’s portfolio.
Other Hedge Funds, Including , Mirae Asset Global Investments Ltd. added FLXN to its portfolio by purchasing 31,746 company shares during the most recent quarter which is valued at $687,301. Flexion Therapeutics Inc makes up approx 0.01% of Mirae Asset Global Investments Ltd.’s portfolio.Proshare Advisors boosted its stake in FLXN in the latest quarter, The investment management firm added 1,330 additional shares and now holds a total of 19,650 shares of Flexion Therapeutics Inc which is valued at $425,423. Flexion Therapeutics Inc makes up approx 0.01% of Proshare Advisors’s portfolio.
Flexion Therapeutics Inc opened for trading at $18.14 and hit $18.59 on the upside on Monday, eventually ending the session at $18.21, with a gain of 0.89% or 0.16 points. The heightened volatility saw the trading volume jump to 6,62,032 shares. Company has a market cap of $501 M.
Many Wall Street Analysts have commented on Flexion Therapeutics Inc. Lake Street Resumed Flexion Therapeutics Inc on Sep 6, 2016 to “Buy”, Price Target of the shares are set at $38.
Flexion Therapeutics Inc. is a specialty pharmaceutical company focused on the development and commercialization of injectable pain therapies. The Company is also focused on anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions such as osteoarthritis (OA) a type of degenerative arthritis. The Company’s portfolio of product candidates addresses the OA pain treatment spectrum from moderate to severe pain. The Company’s products include FX006 which is indicated for front line intra-articular (IA) therapy for patients with moderate to severe OA pain; FX007 which is indicated for post-operative pain and FX005 which is indicated for end-stage OA pain. The Company is conducting a pivotal Phase IIb clinical trial of FX006. The Company is conducting preclinical local pharmacology and toxicology experiments of FX007. FX005 has completed its Phase IIa trials.